{"generic":"Trabectedin","drugs":["Trabectedin"],"mono":{"0":{"id":"930366-s-0","title":"Generic Names","mono":"Trabectedin"},"1":{"id":"930366-s-1","title":"Dosing and Indications","sub":[{"id":"930366-s-1-4","title":"Adult Dosing","mono":"<ul><li>trabectedin has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>criteria for treatment or retreatment (delay therapy for up to 3 weeks until criteria are met):<\/b> absolute neutrophil count 1500\/mm(3) or greater; platelet count 100,000\/mm(3) or greater; bilirubin ULN or less; alkaline phosphatase 2.5 times ULN or less (consider hepatic isoenzymes 5-nucleotidase or gamma glutamyl transpeptidase if the elevation could be osseous in origin); albumin 25 g\/L or greater; ALT and AST 2.5 times ULN or less; CrCl 30 mL or greater (monotherapy), serum creatinine 1.5 mg\/dL (132.6 mcmol\/L) or greater or CrCl 60 mL\/min or greater (combination therapy); CPK 2.5 times ULN or less; Hb 9 g\/dL or greater<\/li><li><b>Ovarian cancer, Relapsed, platinum-sensitive; in combination with pegylated liposomal doxorubicin:<\/b> 1.1 mg\/m(2) IV over 3 hours immediately following pegylated liposomal doxorubicin 30 mg\/m(2) IV at a rate of no greater than 1 mg\/min (initial infusion) and over 1 hour (subsequent infusions if no infusion reaction with first infusion) every 3 weeks; premedicate with corticosteroid IV 30 minutes prior to pegylated liposomal doxorubicin (European Medicines Agency-approved dosing)<\/li><li><b>Sarcoma of soft tissue, Advanced, after failure or unable to receive anthracyclines and ifosfamide:<\/b> 1.5 mg\/m(2) IV over 24 hours every 3 weeks; premedicate with corticosteroid IV 30 minutes prior to infusion (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930366-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients younger than 18 years "},{"id":"930366-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild or moderate:<\/b> no dose adjustment required<\/li><li><b>elderly:<\/b> no dose adjustment required<\/li><li>soft tissue sarcoma, not recommended in patients with CrCl less than 30 mL\/min<\/li><li>soft tissue sarcoma, for bilirubin above ULN, alkaline phosphatase greater than 2.5 times ULN, or AST or ALT greater than 2.5 times ULN, decrease to trabectedin 1.2 mg\/m(2); if toxicity recurs, reduce to trabectedin 1 mg\/m(2); consider discontinuing therapy if toxicity recurs after second reduction<\/li><li>soft tissue sarcoma, for neutropenia less than 500\/mm(3) lasting for more than 5 days or with fever or infection or thrombocytopenia less than 25,000\/mm(3), decrease to trabectedin 1.2 mg\/m(2); if toxicity recurs, reduce to 1 mg\/m(2); consider discontinuing therapy if toxicity recurs after second reduction<\/li><li>soft tissue sarcoma, for any other grade 3 or 4 adverse event, decrease to trabectedin 1.2 mg\/m(2); if toxicity recurs, reduce to trabectedin 1 mg\/m(2); consider discontinuing therapy if toxicity recurs after second reduction<\/li><li>ovarian cancer, not recommended in patients with CrCl less than 60 mL\/min<\/li><li>ovarian cancer, for bilirubin above ULN, alkaline phosphatase greater than 2.5 times ULN, or AST or ALT greater than 5 times ULN, decrease to trabectedin 0.9 mg\/m(2) plus pegylated liposomal doxorubicin 25 mg\/m(2); if toxicity recurs, reduce to trabectedin 0.75 mg\/m(2) plus pegylated liposomal doxorubicin 20 mg\/m(2); consider discontinuing therapy if toxicity recurs after second reduction<\/li><li>ovarian cancer, for neutropenia less than 500\/mm(3) lasting for more than 5 days or with fever or infection or thrombocytopenia less than 25,000\/mm(3), decrease to trabectedin 0.9 mg\/m(2) plus pegylated liposomal doxorubicin 25 mg\/m(2); if toxicity recurs, reduce to trabectedin 0.75 mg\/m(2) plus pegylated liposomal doxorubicin 20 mg\/m(2); consider discontinuing therapy if toxicity recurs after second reduction<\/li><li>ovarian cancer, for any other grade 3 or 4 adverse event, decrease to trabectedin 0.9 mg\/m(2) plus pegylated liposomal doxorubicin 25 mg\/m(2); if toxicity recurs, reduce to trabectedin 0.75 mg\/m(2) plus pegylated liposomal doxorubicin 20 mg\/m(2); consider discontinuing therapy if toxicity recurs after second reduction<\/li><\/ul>"},{"id":"930366-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Ovarian cancer, Relapsed, platinum-sensitive; in combination with pegylated liposomal doxorubicin<\/li><li>Sarcoma of soft tissue, Advanced, after failure or unable to receive anthracyclines and ifosfamide<\/li><\/ul>"}]},"3":{"id":"930366-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930366-s-3-9","title":"Contraindications","mono":"<ul><li>breastfeeding, during and for 3 months after therapy<\/li><li>concomitant use with yellow fever vaccination<\/li><li>hypersensitivity to trabectedin or any component of the product<\/li><li>infection, serious or uncontrolled<\/li><\/ul>"},{"id":"930366-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use with potent CYP3A4 inhibitors, phenytoin, alcohol, and live attenuated vaccines should be avoided<\/li><li>extravasation that may cause tissue necrosis requiring debridement can occur<\/li><li>hypersensitivity reactions, including fatalities, have been reported<\/li><li>injection site reactions may develop with peripheral venous administration; use of central venous access is strongly recommended<\/li><li>liver function test elevations, including bilirubin, have been reported; do not use in patients with pretreatment elevated bilirubin; monitoring recommended; treatment interruption with subsequent dose adjustments may be required<\/li><li>liver disease, including active chronic hepatitis; monitoring recommended; dose adjustment may be necessary<\/li><li>men, fertile; use effective contraception during and 5 months following therapy<\/li><li>neutropenia, including grade 3 and 4, has been reported; monitoring recommended; treatment interruption with subsequent dose adjustments may be necessary<\/li><li>pregnancy; known teratogen; use effective contraception during and 3 months following therapy<\/li><li>renal impairment; use not recommended for pretreatment CrCl less than 30 mL\/min (monotherapy) or pretreatment CrCl less than 60 mL\/min (combination therapy); monitoring recommended; treatment interruption may be necessary<\/li><li>rhabdomyolysis has been reported; monitoring recommended; treatment interruption may be necessary<\/li><li>thrombocytopenia, including grade 3 and 4, has been reported; monitoring recommended; treatment interruption with subsequent dose adjustments may be necessary<\/li><\/ul>"},{"id":"930366-s-3-11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"930366-s-3-12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"4":{"id":"930366-s-4","title":"Drug Interactions","sub":[{"id":"930366-s-4-13","title":"Contraindicated","mono":"<ul><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Yellow Fever Vaccine (theoretical)<\/li><\/ul>"},{"id":"930366-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Adenovirus Vaccine Type 4, Live (theoretical)<\/li><li>Adenovirus Vaccine Type 7, Live (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Influenza Virus Vaccine, Live (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Measles Virus Vaccine, Live (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mumps Virus Vaccine, Live (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Poliovirus Vaccine, Live (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Quercetin (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rotavirus Vaccine, Live (theoretical)<\/li><li>Rubella Virus Vaccine, Live (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Smallpox Vaccine (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Typhoid Vaccine (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Varicella Virus Vaccine (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"930366-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Hand-foot syndrome due to cytotoxic therapy (ovarian cancer, 24%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (ovarian cancer, 20.4%; soft tissue sarcoma, 10% or greater), Diarrhea (ovarian cancer, 17.1%; soft tissue sarcoma, 1% to less than 10%), Inflammatory disease of mucous membrane (ovarian cancer, 11.4%), Loss of appetite (ovarian cancer, 28.8%; soft tissue sarcoma, 10% or greater), Nausea (ovarian cancer, 70.9%; soft tissue sarcoma, 10% or greater), Stomatitis (ovarian cancer, 19.2%; soft tissue sarcoma, 10% or greater), Vomiting (ovarian cancer, 51.7%; soft tissue sarcoma, 10% or greater)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (93% to 94.9%), Leukopenia, All grades (ovarian cancer, 94.9%; soft tissue sarcoma, 10% or greater), Neutropenia, All grades (ovarian cancer, 91.6%; soft tissue sarcoma, 10% or greater), Thrombocytopenia, All grades (ovarian cancer, 63.7%; soft tissue sarcoma, 10% or greater)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised (ovarian cancer, 61.3%; soft tissue sarcoma, 10% or greater), ALT\/SGPT level raised (ovarian cancer, 96.1%; soft tissue sarcoma, 10% or greater), AST\/SGOT level raised (ovarian cancer, 89.5%; soft tissue sarcoma, 10% or greater), Hyperbilirubinemia (ovarian cancer, 25.2%; soft tissue sarcoma, 10% or greater)<\/li><li><b>Musculoskeletal:<\/b>Increased creatine kinase level (23% to 26%)<\/li><li><b>Neurologic:<\/b>Headache (ovarian cancer, 6.6%; soft tissue sarcoma, 10% or greater)<\/li><li><b>Renal:<\/b>Decreased albumin (soft tissue sarcoma, 10% or greater), Serum creatinine raised (soft tissue sarcoma, 10% or greater)<\/li><li><b>Other:<\/b>Asthenia (ovarian cancer, 15.3%; soft tissue sarcoma, 10% or greater), Fatigue (ovarian cancer, 42.3%; soft tissue sarcoma, 10% or greater), Fever (1% to 10.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (grade 3, 10% to 12.9%; grade 4, 3% to 5.7%), Febrile neutropenia, Grade 3 or 4 (ovarian cancer, grade 3, 4.5%; grade 4, 2.4%), Granulocytopenic disorder (ovarian cancer, 1.5%), Leukopenia, Grade 3 or 4 (ovarian cancer, grade 3, 44.7%; grade 4, 17.7%), Neutropenia, Grade 3 or 4 (grade 3, 26% to 29.7%; grade 4, 24% to 42.3%), Neutropenic sepsis (ovarian cancer, less than 1%), Pancytopenia (ovarian cancer, 1.8%), Thrombocytopenia, Grade 3 or 4 (grade 3, 11% 12.3%; grade 4, 2% to 10.8%)<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis (soft tissue sarcoma, less than 1%)<\/li><li><b>Respiratory:<\/b>Pulmonary embolism (ovarian cancer, 1.2%)<\/li><\/ul>"},"6":{"id":"930366-s-6","title":"Drug Name Info","sub":{"2":{"id":"930366-s-6-19","title":"Class","mono":"Antineoplastic Agent<br\/>"},"3":{"id":"930366-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"930366-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>administration through a central venous line is strongly recommended<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute the single-use vials to a concentration of 0.05 mg\/mL; shake until completely dissolved; use reconstituted product immediately<\/li><li>dilute reconstituted solution with NS or D5W; central line administration requires at least 50 mL of diluent for a trabectedin concentration of 0.03 mg\/mL or less; peripheral venous administration requires at least 1000 mL of diluent<\/li><li>ovarian cancer, flush infusion line with D5W after administration of pegylated liposomal doxorubicin and before administration of trabectedin<\/li><li>extravasation may cause tissue necrosis that requires debridement<\/li><\/ul><\/li><\/ul>"}}}